MetriDx uterine biopsy test to find endometriosis biomarkers
Official title: Proof-of-Concept, Obs Study to Evaluate Accuracy of MetriDx Lab Developed Test (LDT) to Accurately Identify Endometriosis-specific Biological Markers Using Micro-fluidic Analysis of Cells Enabling Clinicians to Diagnose Endometriosis
Run by Hera Biotech, Inc. · NCT05698212 · Data updated 2026-11-12
This test tries to see if a simple uterine biopsy sent to a lab and analyzed by MetriDx's AI can detect endometriosis in people who are having or recently had laparoscopy.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 50 Years |
| Sex | Women only |
| Enrollment | 75 (estimated) |
| Sponsor | Hera Biotech, Inc. Industry-sponsored |
| Locations | 3 sites (Saginaw, Michigan and 2 other locations) |
| Status | Recruiting |
| Started | September 14, 2022 |
| Main results expected | March 25, 2023 |
| Study ends | April 10, 2023 |
| Registry record updated | January 26, 2023 |
| Trial ID | NCT05698212 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
People born female, ages 18–50, not pregnant, and either scheduled for laparoscopy for suspected or known endometriosis or undergoing laparoscopy for other reasons are ideal candidates.
✕Probably not a fit
Those who are pregnant, outside the 18–50 age range, have had endometriosis excision/ablation or GnRH treatment within the past 12 months, or who will not undergo laparoscopy are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Participants make two visits and have a brief office uterine biopsy (similar to a Pap smear) before they undergo laparoscopy as part of their clinical care. The biopsy sample is sent to a specialized lab where a proprietary microfluidic and AI-based MetriDx analysis examines cellular biomarkers, including connexins. Results from the MetriDx biopsy are compared to laparoscopy findings to measure diagnostic accuracy. The study enrolls an active group with suspected or known endometriosis and a control group without endometriosis who are having laparoscopy for other reasons.
Why it matters
Potential benefit: If successful, this could offer a less invasive way to diagnose endometriosis using an office uterine biopsy instead of laparoscopy.
How similar studies have gone: Using endometrial samples and molecular biomarkers to detect endometriosis is a relatively new approach with some encouraging preliminary data, but robust validation against laparoscopy is still limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Able to understand and provide informed consent. * Natural born female of childbearing potential. * Age between 18 and 50, inclusive. * Not pregnant at Visit 0 (screening) or Visit 1 (day of procedure). * Free of systemic or pelvic disorder that, in the opinion of the investigator, may interfere with the tissue collection procedure, analysis of the tissue or increase the risk to subject. * Must not have received excision or ablation surgical procedure or treatment, such as gonadotropin-releasing hormone (GnRH), for endometriosis within the past 12 months. * For Cohort 1 and 2: * Suspected of having endometriosis, or previously diagnosed with endometriosis, and currently recommended for laparoscopic surgery by physician. * Must have laparoscopic surgery within 60 days after screening Visit 0 and any time after the endometrial biopsy is obtained on Visit 1 (including the same day), or a laparoscopy on record within the 12 months prior to Visit 0 for diagnosis only. * Surgical report from prior laparoscopy must indicate that endometriosis was not treated with surgical ablation or excision. * Subjects will be assigned to Cohort 1 or 2 based on diagnosis and staging results from laparoscopy. * Or for Cohort 3: * Not suspected of having endometriosis * no previous diagnosis or symptoms of endometriosis, who have had a laparoscopy for another reason, such as tubal ligation or other abdominal procedure, within the past 12 months prior to screening Visit 0, * or laparoscopy to be completed within 60 days after screening Visit 0 and any time after the endometrial biopsy is obtained on Visit 1 (including the same day). * Surgeon's report must have no supplemental observations of endometriosis lesions or diagnosis. Subjects will be assigned to Cohort 3. Exclusion Criteria: * Younger than 18 or 51 years or older. * Surgical history of hysterectomy. * Has received excision or ablation surgical procedure or treatment, such as gonadotropin-releasing hormone (GnRH), for endometriosis within the past 12 months. * Cohort 3: Prior diagnosis of endometriosis, or surgical note from prior laparoscopy that indicates endometriosis lesions were observed. * Has a BMI 40 or above. * Is currently taking a blood thinner medication. * Currently, pregnant, breast feeding, or has given birth in the last 6 months. * Diagnosed with HIV, AIDS, hepatitis A, B, or C, or has active malignancy. * Has a complicating condition that would pose a hazard to tissue handling. * Undergoing fertility or hormone therapy treatments. * History or evidence of uterine fibroids. * History of reproductive cancer. * Has a condition that, in the opinion of the investigator, would confound tissue collection or analysis. * Has an active pelvic infection or other infections contra-indicated for laparoscopy. * Has participated in any interventional clinical trial in the previous 90 days in which an investigational drug was administered. * Has a history of alcohol or illegal drug/substance abuse, or suspected alcohol or illegal drug/substance abuse in the past two years.
Where it's running
-
Corpus Christi Women's Center
Corpus Christi, Texas, United States Recruiting -
University of Texas Physician's Women's Center--Memorial City
Houston, Texas, United States Recruiting -
Valley OB-GYN Clinic, PC
Saginaw, Michigan, United States Not yet recruiting
Study contacts
- Principal investigator: Sandra M Hurtado, MD — University of Texas Physicians Women's Center
- Study coordinator: Janan Van Osdell, MHSA
- Email: janan@tammnet.com
- Phone: 855-826-6638
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI analysis of ECGs to detect structural heart disease
This project will test whether AI can read traditional and wearable ECGs to find undiagnosed valve disease, pulmonary hypertension, and heart failure in adults.
-
Comparing different techniques to treat endometriosis
This study is testing different methods to treat endometriosis, like laser and heat techniques, to see which one works best for relieving pain in women who are already having surgery for the condition.
-
Postoperative Pain Trajectories After Endometriosis Surgery
This study tests how pain changes after endometriosis surgery and whether perioperative pain testing can predict who will have ongoing pain.
-
Imaging endometriosis with a special PET tracer in adult women
This study tests whether a PET/CT scan using [18F]AlF-FAPI-74 can help detect endometriosis lesions in women who are planning laparoscopy.
-
Fiber supplement for digestive symptoms in endometriosis
A fiber-based supplement is being tested to see if it is safe and helps with gut and vaginal microbiomes and digestive symptoms in women with endometriosis.
-
Stellate ganglion block and dexmedetomidine for better sleep after gynecologic laparoscopy
The study tests whether giving a preoperative stellate ganglion block plus intraoperative dexmedetomidine improves sleep after laparoscopic gynecologic surgery in women.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.